Our project portfolio
Galenicap specializes in developing so-called Value-Added Medicines (VAMs), which are advanced versions of existing drugs, offering improved efficacy and safety, and new therapeutic applications. VAMs aim to provide novel, cost-effective treatment options for patients, and cost savings for healthcare providers and payors. VAMs can be created through different approaches, with drug reformulation involving improved formulations and drug repurposing redirecting drugs to new uses. New Therapeutic Entities (NTEs) combine these strategies to reformulate existing medicines for new therapeutic indications, forming the core of Galenicap's product portfolio.
Most of our NTE development programs originate from collaborations with prestigious universities, medical schools and smaller specialty pharma firms. In recent years, drug repurposing has indeed gained substantial traction due to its budget constraints and expedited development timelines, particularly compared to new NCE or biotech product development. However, reliance only on existing, commercially available dosage forms presents challenges, as protection through 'use patents' is rather limited. By incorporating a drug reformulation strategy, Galenicap unlocks the potential to create unique products with a robust intellectual property (IP) position that aligns perfectly with the new therapeutic indications being targeted.
Before embarking on new development programs, candidate projects undergo a thorough evaluation process. This includes the validation of clinical necessity and Target Product Profile, an assessment of technical feasibility, scrutiny of the IP landscape and market exclusivity, examination of the regulatory pathway, formulation of an appropriate go-to-market strategy, and exploration of opportunities for commercialization or partnerships. This comprehensive procedure involves close collaboration with external experts and insights from clinical KOLs. Furthermore, the evaluation process takes into account factors such as development costs, portfolio diversification, and a strong emphasis on addressing unmet clinical needs. The objective is to efficiently advance products, maintain a well-balanced portfolio, and prioritize impactful contributions to healthcare.